September 29, 2009 (FinancialWire) — Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, announced the closing of its underwritten public offering of 4,600,000 shares of its common stock, which includes the full exercise of the underwriter’s over-allotment option of 600,000 shares.

After underwriting discounts and commissions and estimated offering expenses, Momenta received net proceeds of approximately $46.7 million. Leerink Swann LLC acted as sole book-running manager for the offering. The shares were sold pursuant to the company’s existing shelf registration statement, base prospectus, and prospectus supplement as filed with the Securities and Exchange Commission.

Momenta Pharmaceuticals is a biotechnology company, headquartered in Cambridge, MA, specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.